特利加压素联合前列地尔对肝硬化难治性腹水患者肝肾功能的影响

Effects of terlipressin combined with alprostadil on hepatic and renal function in liver cirrhosis patients with refractory ascites

目的探讨特利加压素联合前列地尔对肝硬化难治性腹水患者肝肾功能的影响。方法选择74例肝硬化难治性腹水患者,随机分为2组。对照组行前列地尔治疗,观察组在此基础上联用特利加压素,比较2组治疗前与治疗2周后肝肾功能指标变化情况与门静脉内径与脾静脉内径。结果观察组治疗2周后尿氮素(BUN)、血肌酐(Scr)含量均显著低于对照组,24 h尿量显著高于对照组(P<0.05);观察组患者治疗2周后白蛋白(ALB)水平显著高于对照组,总胆红素(TBIL)水平显著低于对照组(P<0.05);观察组治疗2周后门静脉内径与脾静脉内径均显著低于对照组(P<0.05)。结论特利加压素与前列地尔联合治疗肝硬化难治性腹水患者效果显著。

Objective To explore effect of terlipressin combined with alprostadil on hepatic and renal function in liver cirrhosis patients with refractory ascites. Methods A total of 74 liver cir- rhosis patients with refractory ascites were randomly divided into two groups. The control group re- ceived alprostadil treatment, while observation group was treated with terlipressin on the basis of con- trol group. Before treatment and after 2 weeks of treatment, liver and kidney function indexes, inner diameter of portal vein and splenic vein diameter were compared. Results In the observation group, the BUN and 5cr contents after 2 weeks of treatment were significantly lower than the control group, and 24 h urine volume was significantly higher than the control group （P 〈 0.05 ）. After 2 weeks of treatment, the level of ALB in the observation group was significantly higher than the control group, while the TBIL level was significantly lower than the control group （ P 〈 0.05 ）. After 2 weeks of treatment, the portal vein diameter and inside diameter of splenic vein in the observation group were significantly lower than the control group （ P 〈 0.05 ）. Conclusion Terlipressin combined with al- prostadil is effective in treatment of liver cirrhosis patients with refractory ascites.